NCT00134082View on ClinicalTrials.gov

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Lymphoma
Interventions
BIOLOGICAL

KGEL vaccine

Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10\^8 cells per dose. The first dose was given on Day +1.

BIOLOGICAL

Filgrastim

5 mcg/kg/day starting on Day +6 until ANC is \>= 1000/mcL.

BIOLOGICAL

Rituximab

375 mg/m\^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.

DRUG

Cyclophosphamide

50 mg/kg/day on Day -3, -2, -1, and 0.

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00134082 - Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter